- Further broadens the uses and applications
of IceCure's cryoablation platform into a wide range of
technology fields
- Over 50 patents issued and
allowed worldwide for IceCure's platform cryoablation
technology
CAESAREA, Israel, Aug. 28,
2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:
ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of
minimally-invasive cryoablation technology that destroys tumors by
freezing as an alternative to surgical tumor removal, today
announced it has received a Notice of Allowance from the U.S.
Patent and Trademark Office ("USPTO") for a continuation
application based on the Company's issued patent titled "Cryogen
Pump". The original patent, which was also issued by the European
Patent Office and the Japan Patent Office, as well as the
continuation, will be in effect until 2041.
"This new patent will support IceCure's potential for increasing
the number of indications, procedures and applications that can be
performed with our next-generation industry-leading platform
cryoablation systems," stated IceCure Chief Executive Officer
Eyal Shamir. "We believe that
further fortifying our cryoablation intellectual property ("IP")
estate in the U.S. is well timed both with respect to the
indications for which we already have U.S. Food and Drug
Administration ("FDA") approval as well as the FDA's decision on
clearance for early-stage breast cancer, the decision which we
expect in the first quarter of next year."
IceCure's novel cryogenic pump is submersible in liquid
nitrogen, works in a closed circuit, improves the cooling rate
during a procedure, and is designed to be used for multiple
procedures or longer duration procedures without the need to refill
liquid nitrogen. Moreover, this pump enables the use of a wider
range of cryoprobes and catheters. The pump has been integrated
into IceCure's next-generation XSense™ cryoablation system.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM)
develops and markets advanced liquid-nitrogen-based cryoablation
therapy systems for the treatment of tumors (benign and cancerous)
by freezing, with the primary focus areas being breast, kidney,
bone and lung cancer. Its minimally invasive technology is a safe
and effective alternative to hospital surgical tumor removal that
is easily performed in a relatively short procedure. The Company's
flagship ProSense® system is marketed and sold worldwide for the
indications cleared and approved to date including in the U.S.,
Europe and China.
Forward Looking Statements
This press release
contains forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and other Federal securities laws. Words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates"
and similar expressions or variations of such words are intended to
identify forward-looking statements. For example, IceCure is using
forward looking statements in this press release when it discusses
the Company's leadership in cryoablation technologies; IceCure's
potential for expanding the number of indications, procedures and
applications that can be performed with the Company's
next-generation industry-leading platform cryoablation systems; the
FDA's decision on clearance for early-stage breast cancer expected
to be received in the first quarter of 2025; the potential benefits
of the Company's novel cryogenic pump; and the belief that
fortifying IceCure's cryoablation IP estate in the U.S. is well
timed. Historical results of scientific research and clinical and
preclinical trials do not guarantee that the conclusions of future
research or trials will suggest identical or even similar
conclusions. Important factors that could cause actual results,
developments and business decisions to differ materially from those
anticipated in these forward-looking statements include, among
others: the Company's planned level of revenues and capital
expenditures; the Company's available cash and its ability to
obtain additional funding; the Company's ability to market and sell
its products; legal and regulatory developments in the United States and other countries; the
Company's ability to maintain its relationships with suppliers,
distributors and other partners; the Company's ability to maintain
or protect the validity of its patents and other intellectual
property; the Company's ability to expose and educate medical
professionals about its products; political, economic and military
instability in the Middle East,
specifically in Israel; as well as
those factors set forth in the Risk Factors section of the
Company's Annual Report on Form 20-F for the year ended
December 31, 2023 filed with the SEC
on April 3, 2024, and other documents
filed with or furnished to the SEC which are available on the SEC's
website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/uspto-grants-notice-of-allowance-for-additional-patent-on-icecures-novel-cryogenic-pump-technology-reinforces-icecures-global-ip-leadership-in-cryoablation-technologies-302232712.html
SOURCE IceCure Medical